Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Health Yuan launches a new generation of glucocorticoid innovative drug, achieving another milestone in its innovative drug pipeline.
Published Time：
2024-10-31
Recently, HealthGen Biotech Group announced the launch of a novel small molecule glucocorticoid drug. This drug targets respiratory diseases such as COPD, bronchial asthma, and rhinitis, and can provide patients with a more effective treatment plan by activating specific receptor activity. Data shows that in a mouse OVA asthma model, the drug showed efficacy more than 3 times that of existing clinically used glucocorticoids, showing the potential to become a Best-in-Class drug. This achievement marks significant progress made by Chinese companies in the global research and development of the next generation of glucocorticoids.
In China, a large number of patients' lives are affected by inflammatory diseases, especially in the respiratory tract. Inflammatory diseases such as COPD and asthma affect a large population, far exceeding 100 million. Glucocorticoids, as endogenous anti-inflammatory small molecules, can act on glucocorticoid receptors (GR), regulating the transcription of inflammation-related genes to inhibit the expression of inflammatory factors and suppress immune cell proliferation. The new anti-inflammatory glucocorticoid drug launched by HealthGen can effectively improve efficacy and reduce adverse reactions, and is expected to become a new treatment option for patients with COPD, bronchial asthma, and rhinitis.
HealthGen has always adhered to innovative development and continuously increased investment in innovative drug research and development. The launch of the new glucocorticoid not only further deepens the company's layout of innovative drug pipelines in the respiratory field but also injects new vitality and impetus into the company's innovative R&D system. At the same time, the company stated that it will give full play to its technological and resource advantages to accelerate the subsequent development of this product, striving to achieve commercialization as soon as possible, so that this innovative drug can benefit more patients suffering from diseases as soon as possible, and contribute more to promoting the development of China's pharmaceutical industry and safeguarding people's health.
This article is from: Securities Market Weekly Market Number
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.